Related Experiment Video
Updated: Jul 1, 2025
05:51
Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
Published on: October 14, 2021
3.8K
Levodopa-Carbidopa-Entacapone Intestinal Gel in Advanced Parkinson Disease: A Multicenter Real-Life Experience
József Attila Szász1,2, Adriana Octaviana Dulamea3,4, Viorelia Adelina Constantin2
1Department of Neurology, "George Emil Palade" University of Medicine, Pharmacy, Science and Technology, Târgu Mureş, Romania.
American Journal of Therapeutics
|March 9, 2024
Summary
Levodopa-entacapone-carbidopa intestinal gel (LECIG) infusion effectively reduces off time and dyskinesias in advanced Parkinson disease (APD). This therapy simplifies treatment regimens for APD patients in real-world clinical practice.
Area of Science:
- Neurology
- Gastroenterology
- Pharmacology
Background:
- Advanced Parkinson disease (APD) presents challenges for medication management.
- Device-aided therapies (DAT), including deep brain stimulation and infusion therapies, offer continuous dopaminergic stimulation.
- Levodopa-entacapone-carbidopa intestinal gel (LECIG) infusion is a recent DAT approved in Romania for APD.
Purpose of the Study:
- To evaluate the real-world clinical experience with LECIG in Romania for APD patients.
- To assess the efficacy and tolerability of LECIG in managing advanced Parkinson disease symptoms.
Main Methods:
- Retrospective evaluation of 74 APD patients across 12 specialized centers in Romania.
- Collected demographic and clinical data, including cognitive assessments and medication dosages.
- Assessed reduction in daily off time, motor fluctuations, dyskinesias, and use of concomitant medications.
Main Results:
- LECIG significantly reduced daily 'off' time from 5.7 to 1.7 hours (P < 0.01).
- Significant reductions in the duration and severity of dyskinesias were observed.
- LECIG treatment allowed for a significant decrease in the use of concomitant oral Parkinson's medications.
Conclusions:
- Levodopa-entacapone-carbidopa intestinal gel (LECIG) is an effective device-aided therapy for advanced Parkinson disease.
- LECIG treatment can simplify the overall treatment regimen for patients with advanced Parkinson disease.
- Real-world data supports LECIG as a valuable therapeutic option for managing APD.
Related Concept Videos
01:24Parkinson's Disease: Treatment
268
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
268
01:15Parkinson's Disease: Overview
544
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
544
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
315
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
315
01:15Enteral Nutrition II: Nasointestinal and Gastrostomy Feeding
132
Enteral nutrition encompasses various methods of delivering nutrition directly to the gastrointestinal (GI) tract, bypassing traditional oral intake. It is particularly beneficial for patients who cannot eat by mouth but have a functioning digestive system. Key methods include nasointestinal feeding, gastrostomy, and jejunostomy, each suited to different clinical scenarios based on the patient's needs and condition.
Nasointestinal Feeding
Nasointestinal feeding involves placing a tube...
Nasointestinal Feeding
Nasointestinal feeding involves placing a tube...
132
01:17Drugs for Treatment of Diarrhea-Predominant IBS
169
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
169
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
252
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
252